Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy.
The success of cellular immunotherapies against cancer requires the generation of activated CD4⁺ and CD8⁺ T-cells. The type of T-cell response generated (e.g., Th1 or Th2) will determine the efficacy of the therapy, and it is generally assumed that a type-1 response is needed for optimal cancer treatment. IL-17 producing T-cells (Th17/Tc17) play an important role in autoimmune diseases, but their function in cancer is more controversial. While some studies have shown a pro-cancerous role for IL-17, other studies have shown an anti-tumor function. The induction of polarized T-cell responses can be regulated by dendritic cells (DCs). DCs are key regulators of the immune system with the ability to affect both innate and adaptive immune responses. These properties have led many researchers to study the use of ex vivo manipulated DCs for the treatment of various diseases, such as cancer and autoimmune diseases. While Th1/Tc1 cells are traditionally used for their potent anti-tumor responses, mounting evidence suggests Th17/Tc17 cells should be utilized by themselves or for the induction of optimal Th1 responses. It is therefore important to understand the factors involved in the induction of both type-1 and type-17 T-cell responses by DCs.
Department of Surgery and Harrison Department of Surgical Research, University of Pennsylvania, Philadelphia, PA 19104, USA. jterhune@smail.umaryland.edu.
Julia
J
Terhune
Department of Surgery and Harrison Department of Surgical Research, University of Pennsylvania, Philadelphia, PA 19104, USA. erik.berk@uphs.upenn.edu.
Erik
E
Berk
Department of Surgery and Harrison Department of Surgical Research, University of Pennsylvania, Philadelphia, PA 19104, USA. brian.czerniecki@uphs.upenn.edu.|Rena Rowan Breast Center, University of Pennsylvania, Philadelphia, PA 19104, USA. brian.czerniecki@uphs.upenn.edu.
Brian J
BJ
Czerniecki
cancer; dendritic cell vaccine; immunotherapy